Literature DB >> 18421059

Major response to imatinib mesylate in KIT-mutated melanoma.

F Stephen Hodi1, Philip Friedlander, Christopher L Corless, Michael C Heinrich, Suzanne Mac Rae, Andrea Kruse, Jyothi Jagannathan, Annick D Van den Abbeele, Elsa F Velazquez, George D Demetri, David E Fisher.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18421059     DOI： 10.1200/JCO.2007.14.0707

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  126 in total

Review 1.  Melanoma: from mutations to medicine.

Authors:  Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

Review 2.  Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics.

Authors:  Scott E Woodman; Michael A Davies
Journal:  Biochem Pharmacol       Date:  2010-05-08       Impact factor: 5.858

Review 3.  Mucosal melanoma: pathogenesis, clinical behavior, and management.

Authors:  Michael A Postow; Omid Hamid; Richard D Carvajal
Journal:  Curr Oncol Rep       Date:  2012-10       Impact factor: 5.075

Review 4.  Clinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challenges.

Authors:  Laura E MacConaill; Paul Van Hummelen; Matthew Meyerson; William C Hahn
Journal:  Cancer Discov       Date:  2011-09       Impact factor: 39.397

Review 5.  New strategies in melanoma: molecular testing in advanced disease.

Authors:  Scott E Woodman; Alexander J Lazar; Kenneth D Aldape; Michael A Davies
Journal:  Clin Cancer Res       Date:  2012-01-24       Impact factor: 12.531

Review 6.  From genes to drugs: targeted strategies for melanoma.

Authors:  Keith T Flaherty; F Stephen Hodi; David E Fisher
Journal:  Nat Rev Cancer       Date:  2012-04-05       Impact factor: 60.716

Review 7.  A brief history of melanoma: from mummies to mutations.

Authors:  Vito W Rebecca; Vernon K Sondak; Keiran S M Smalley
Journal:  Melanoma Res       Date:  2012-04       Impact factor: 3.599

8.  Smad7 restricts melanoma invasion by restoring N-cadherin expression and establishing heterotypic cell-cell interactions in vivo.

Authors:  Kyle A DiVito; Valerie A Trabosh; You-Shin Chen; Yu Chen; Chris Albanese; Delphine Javelaud; Alain Mauviel; Cynthia M Simbulan-Rosenthal; Dean S Rosenthal
Journal:  Pigment Cell Melanoma Res       Date:  2010-08-25       Impact factor: 4.693

9.  High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes.

Authors:  Edwin Choy; Francis Hornicek; Laura MacConaill; David Harmon; Zeeshan Tariq; Levi Garraway; Zhenfeng Duan
Journal:  Cancer       Date:  2011-10-17       Impact factor: 6.860

10.  SRC family kinase inhibition as a novel strategy to augment melphalan-based regional chemotherapy of advanced extremity melanoma.

Authors:  Yoshihiro Tokuhisa; Michael E Lidsky; Hiroaki Toshimitsu; Ryan S Turley; Georgia M Beasley; Tomio Ueno; Ketan Sharma; Christina K Augustine; Douglas S Tyler
Journal:  Ann Surg Oncol       Date:  2013-11-27       Impact factor: 5.344
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.